Phase Holographic: Harvard Medical School spotlight HoloMonitor-based research

See news

Harvard Medical School recently spotlighted that scientists with HoloMonitor have been able to discriminate aggressive blood vessel forming tumor cells from more harmless tumor cells, lacking this ability. Read the article here.

“Our hope is that one day, this technology [HoloMonitor] can provide useful clinical information that could be used to guide personalized therapies based on someone’s precise tumor phenotype [characteristics], said Jing Huang, scientist at Boston Children’s Hospital.

For more information about the research at Boston Children’s Hospital see CEO commentary “No Blood, No Tumor” and the article PHI:s HoloMonitor möjliggjorde amerikanskt forskningsgenombrott.

For additional information, please contact:
Peter Egelberg, CEO

Tel: +46 703 19 42 74

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.

See news  Further information about Phase Holographic

Publicerat: 6/21/2017 8:35:13 AM

Nyheten distribueras av AktieTorget i samarbete med Cision.
För att prenumerera på nyheter på detta bolag, klicka här.

  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se